Patients already taking 2.5 mg BID, avoid coadministration with strong dual inhibitors. • Discontinuing eliquis in patients without adequate continuous anticoagulation increases risk of stroke.

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

With the emergence and approval of other new oral anticoagulants such as dabigatran and rivaroxaban, the role of and place in therapy for all of these new agents will have to be clearly delineated.